Although Hsp90 inhibitors were developed as bona fide anti‐cancer drugs, the BCL1 lymphoma cells, which we used to study the GvT effect in our model, did not respond to the short‐term Hsp90 inhibitor treatment we applied to the mice in order to modulate the allogeneic T cell response in the recipient. The gene discussed is CCND1; the disease is cancer.